Notal Vision has initiated the first U.S. clinical study of its patient-operated OCT system that can be used at home to monitor wet age-related macular degeneration, the company announced in a press release.
Patients with visual acuity as low as 20/400 are being enrolled in the trial at Elman Retina Group in Baltimore.
“Early user experience results indicate that elderly patients with advanced AMD and reduced visual acuity can effectively self-operate the Notal Home OCT with minimal training,” Michael J. Elman, MD, the study’s principal investigator, said in the release.
The company has leveraged expertise from Wasatch Photonics regarding modular OCT system design to develop the “OCT engine,” a key component of the Notal Home OCT system, which includes a lightweight, patient-operated device designed to be used by elderly, visually impaired patients, the release said. The device generates OCT images that are analyzed by an artificial intelligence algorithm at the Notal Vision Diagnostic Clinic, and the patient’s physician will have access to the daily tests.
“The initiation of our first U.S.-based home OCT clinical trial is an important step towards bringing this leading-edge technology to [exudative] AMD patients, their caregivers and the eye care community,” Susan Orr, OD, Notal Vision chief medical officer and incoming CEO, said in the release.